III Manulife

Group Benefits Drug Prior Authorization Rybelsus (Semaglutide)

The purpose of this form is to obtain the medical information required to assess your request for a drug on the Prior Authorization list under your drug plan benefit coverage. To avoid delays in processing your request, please ensure that all information, including contact information is complete. Completion of this form is not a guarantee of approval. If you have already purchased the drug, please attach all original receipts along with an **Extended Health Care Claim** form. All costs incurred to complete this form are the plan member's responsibility. If you are registered for the Plan Member Secure Site and have provided an email address, you will receive an email notification when the prior authorization decision is available on your claims statement. If you are not registered on the Plan Member Secure Site, you will be notified of the prior authorization decision by mail.

Important: Please ensure the most current unaltered version of the form is completed and signed. To download the most recent version of the Drug Prior Authorization form go to <u>www.manulife.ca</u>

To be completed by plan member Plan member address (number, street and apt.) City or town						
Plan member address (number, street and apt.) City or town Province Patient name (first, middle initial, last) Patient date of birth (dd/mmm/yyyy) Re Patient's preferred daytime phone number Patient's email address (optional) Patient's email address (optional) Does the patient have drug coverage under any other group plan? If yes,	Plan member name (first, middle initial, last) Date of birth (dd/mmm/yyyy)					
Patient name (first, middle initial, last) Patient date of birth (dd/mmm/yyyy) Re Patient's preferred daytime phone number Patient's email address (optional) Does the patient have drug coverage under any other group plan? If yes,						
Patient's preferred daytime phone number Patient's email address (optional) Does the patient have drug coverage under any other group plan? If yes,	Postal code					
Does the patient have drug coverage under any other group plan? If yes,	elationship to plar	n member				
lf yes,						
Name of insurance company	⊖ Yes	◯ No				
Plan contract number Plan member certificate number						
Is this drug covered under the other group plan?	Is this drug covered under the other group plan? O Yes O No					
If <i>no</i> , why was the drug declined by the other group plan? Please attach the other group pl (typically a letter or statement). We need this decline notice to see if this drug can be appulf this is a renewal a current decline notice is required.						
Did your plan sponsor recently transfer your drug benefits to Manulife?	⊖ Yes	🔿 No				
Before joining Manulife, were you receiving coverage for this drug through your previous insurance company?	◯ Yes	◯ No				
If yes,						
Attach proof of payment (a copy of a pharmacy receipt showing payment from prior insu Explanation of Benefits from the prior insurance company). Proceed to section 7.	surance comp	any or an				
If <i>no</i> applies to any of the above two questions,						
Proceed to section 2.						

2	Provincial Plans To be completed by prescribing	Most provinces offer some form of drug coverage to their residents. Your Manulife drug plan supplements the coverage provided by provincial plans. It is important that you or your doctor (if required) apply to the applicable provincial program to ensure there are no delays in your drug reimbursement.						
	physician	Check with your doctor or login to the Manulife Provincial Drug Plans Resource Centre on our Plan Member Secure Site at <u>www.manulife.ca/planmember</u> to confirm if the drug you have been prescribed may be eligible for coverage under a provincial plan. If the drug you have been prescribed is listed under a provincial program, you will need to apply to the program before consideration can be given under your Manulife drug plan.						
		Has application been made to the provincial program for coverage? O Yes O N						
		If <i>no</i> , why?						
		Has the patient been approved for coverage by the pr	ovincial program for this	drug?	⊖ Yes	◯ No		
		in no, advise why the request was declined						
		In Ontario, for patients that qualify for coverage under the Exceptional Access Program (EAP), if the drug is an EAP drug, a copy of the approval or denial from EAP must be submitted with this form so Manulife can complete the assessment of this request.						
3	Patient Assistance Programs	Have you enrolled in the Patient Assistance Program?			⊖ Yes	◯ No		
	To be completed by plan member	If <i>yes</i> , please provide your Patient Assistance Program Case Manager name and contact details	m ID Number:					
4	Medical information	Drug strength and dosage						
	To be completed by prescribing	Where will the treatment be administered?						
physician a construction of the construction o					spital/Out	tal/Out-patient		
		Is the MD office located in a hospital?						
		Will the drug be administered in the MD office or in another area of the hospital? (describe below)						
		If the treatment is not being administered at home, please provide: Name of private clinic/hospital Telephone number						
		Address (number, street and apt.)	City or town	Province	Postal code			

4 Medical information (continued)

To be completed by prescribing physician

Please select the diagnosis for which the drug has been prescribed and respond to the corresponding questions.

Type 2 Diabetes Mellitus

🔘 Initial Criteria

Does patient have a confirmed diagnosis of type 2 diabetes mellitus?	⊖ Yes	\bigcirc No				
Was adequate glycemic control achieved with diet and exercise and maximal tolerated dose of metformin?	◯ Yes	⊖ No				
Does patient have documented intolerance or contraindication to metformin?	\bigcirc Yes	\bigcirc No				
Will Rybelsus be used as monotherapy?	⊖ Yes	\bigcirc No				
Will Rybelsus be used in combination with other medicinal products for the treatment of diabetes?	⊖ Yes	⊖ No				
Will Rybelsus be used in combination with other GLP-1 analogs?	⊖ Yes	\bigcirc No				
Will Rybelsus be used as an adjunct to diet and exercise?	⊖ Yes	\bigcirc No				
Will the dose of Rybelsus exceed 14 mg once daily?	⊖ Yes	\bigcirc No				
Note: Initial approval is limited to 12 months. Additional information is required after 12 months in order to assess for further coverage.						
○ Renewal Criteria						
Is there documented objective evidence of continued benefit for the patient (i.e., patient has a decrease in HbA1c)?	⊖ Yes	⊖ No				
Does patient have documented intolerance or contraindication to metformin?	⊖ Yes	🔿 No				
Will Rybelsus be used as monotherapy?	◯ Yes	🔿 No				
Will Rybelsus be used in combination with other medicinal products for the treatment of diabetes?	⊖ Yes	◯ No				
Will Rybelsus be used in combination with other GLP-1 analogs?	⊖ Yes	\bigcirc No				
Will the dose of Rybelsus exceed 14 mg once daily?	\bigcirc Yes	⊖ No				

Any other diagnosis

Please provide the specific diagnosis and any Canadian clinical research that supports the use of this drug in your patient's context.

5	Drug history	If no previous therapies have been tried for the selected diagnosis, please specify the rationale:						
	To be completed by prescribing physician	 Risk of drug interaction Patient has contraindication Other Please provide medical rationale For the selected diagnosis, please provide all previous and current drug therapies in the area below. 						
		Drug name Start date (yyyy/mmm) Please specify the outcome: Intolerance (Allergy/Adverse Event) Inadequa			′mmm)	End date (yyyy/n	nmm)	
					Inadequate	 /Suboptimal F	Response	
		Will the patient be continuin	g on this medication in a	ddition to r	new therapy?		🔿 Yes 🔿 No	
		Drug name			Start date (yyyy)	′mmm)	End date (yyyy/mmm)	
		Please specify the outcome:	Intolerance (Allerg	gy/Adverse	Event) 🔘	Inadequate	/Suboptimal F	Response
		Will the patient be continuin	g on this medication in a	ddition to r	new therapy?		\bigcirc Yes	🔿 No
		Drug name			Start date (yyyy,	/mmm)	End date (yyyy/n	nmm)
		Please specify the outcome:	Intolerance (Allerg	gy/Adverse	Event) 🔘	Inadequate	/Suboptimal F	Response
		Will the patient be continuin	g on this medication in a	ddition to r	new therapy?		⊖ Yes	⊖ No
6	Physician information	Prescribing physician's name Specialty			cialty			
	To be completed by prescribing physician	Address (number, street and suite)		City or town		Province	Postal code	
		Telephone number	Extension	Fax num	ber			
this statement will be kept in a Group Benefits heal			n a Group Benefits health ess has been granted or	and complete to the best of my knowledge. The information in ealth file with Manulife and might be accessible by the patient ed or those authorized by law. By providing the information, ation contained herein.				
							Date signed (dd/	′mmm/yyyy)
7	Authorization and Plan member signature	<u>I certify</u> that I, my spouse and/or my dependents of minor or major age ("Dependents") require the drug named on this form (or an equivalent drug that Manulife proposes).						
	To be signed by plan member	 Lauthorize: Manulife and/or its service providers, its reinsurers, and their service providers to collect, use, maintain and disclose my personal information related to this application ("Personal Information") for the purposes of: The assessment of the drug authorization request. Managing my Group Benefits plan. Assessing and processing claims. Auditing and investigation of claims. Patient assistance programs, if applicable. And/or other purposes identified in the Personal Information Statement for Employers' Group Benefits plans (collectively, the "Purposes"). Any person or organization who has Personal Information about me that is required for Manulife to assess 						
		this drug authorization request, including any medical and health care professionals, institution, pharmacy or any other medical or health care related facility, professional regulatory bodies, any employer, group plan administrator, insurer, investigative agency, and any other administrators of other benefits programs to collect, use, maintain, disclose and exchange this information with each other and with Manulife, its reinsurers and/or its service providers, for the Purposes.					macy p plan o collect,	

 Authorization and Plan member signature (continued) To be signed by plan member 	 Iunderstand: One of Manulife's approved pharmacy partners may engage me in the capacity of case management to provide support as part of this program. I acknowledge that participation in this program is entirely voluntary. My decision to participate will not have any impact on the assessment of my claim. If my Manulife plan recommends purchasing a drug that requires prior authorization from a preferred pharmacy or provider, a case manager may contact me, my doctor and/or patient assistance program to arrange to have my prescription(s) transferred to the preferred pharmacy or provider. That except where there are contractual restrictions, Manulife employees, authorized organizations, service providers and reinsurers are located both within Canada and outside of Canada. Therefore, my Personal Information may be subject to interprovincial or cross-border transfers for the Purposes and may be subject to the laws of those jurisdictions. I may withdraw my consent for certain uses of my Personal Information, subject to legal and contractual restrictions. If I do so, Manulife may treat my withdrawal of consent as a request to dismiss, rescind or terminate my claim. I agreee: A photocopy or electronic version of this consent is valid. I have the right to access and verify my Personal Information maintained in Manulife's files and to request any factually inaccurate Personal Information be corrected, if appropriate. Requests can be sent to: Privacy Officer Manulife, P.O. Box 1602, Del Stn 500-4-A, Waterloo, Ontario N2J 4C6 or Canada_Privacy@manulife.ca. For more information, I can review the Personal Information Statement for Employers' Group Benefits Plans and the Canadian Privacy Policy. Iconfirm that: The information I have				
	Plan member's signature	Date signed (dd/mmm/yyyy)			
	 Protecting your personal information is important to us. People who can see your personal information are: Manulife employees who need to see your information to do their jobs. People you've given permission to. To find out more about Manulife's privacy policy please see <u>manulife.ca</u> 				
8 Mailing instruction	Use the Submit a Claim Feature on the Plan N OR mail or fax your completed form to the ap				
	If you live in Quebec:	If you live outside Quebec:			
	Manulife Group Benefits Health Claims Attention Prior Authorization Team PO BOX 2580, STATION B MONTREAL QC H3B 5C6	Manulife Group Benefits Healt Attention Prior Authorization To PO BOX 1653 WATERLOO ON N2J 4W1			
	Fax: 1-855-752-0404	Fax: 1-855-752-0404			
	Please retain a photocopy for your files.				

Manulife, Manulife & Stylized M Design, and Stylized M Design are trademarks of The Manufacturers Life Insurance Company and are used by it, and by its affiliates under license. © 2025 The Manufacturers Life Insurance Company. All rights reserved. Manulife, PO Box 670, Stn Waterloo, Waterloo, ON N2J 4B8. <u>manulife.ca</u> 1-800-268-3763